Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment
6 Months
N/A
Both
Metastatic Solid Tumors (Any Localization)
Trial Information
Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment
Inclusion Criteria:
- Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable
- Age > 6 months
- PS 0/1 or Lansky play scale >= 70%
- Minimum one treatment line, no limit in the prior number of treatment line
- Evaluable or measurable disease
Exclusion Criteria:
- Life expectancy < 3 months
- Symptomatic or progressive radiologic brain metastasis for non-CNS tumors
- Polynuclear neutrophil < 1 x 10^9/L
- Platelets < 100 x 10^9/L
- Hemoglobin < 90 g/L
- ALT/AST > 2.5 N
- bilirubin > 1.5 N
- Creatinine >1.5 N
- Calcemia > ULN
- Phosphate > ULN
- Coagulation anomaly non-indicated for biopsy
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Progression free survival (PFS) using a targeted treatment selected by molecular profiling compared to the PFS for the most recent regimen
Outcome Description:
Progression according to RECIST criteria or clinical progression or death of any cause
Outcome Time Frame:
From date of start of targeted treatment oriented by MOSCATO until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year
Safety Issue:
No
Principal Investigator
Jean-Charles SORIA, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Gustave Roussy, Cancer Campus, Grand Paris
Authority:
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study ID:
2011-A00841-40
NCT ID:
NCT01566019
Start Date:
October 2011
Completion Date:
October 2015
Related Keywords:
- Metastatic Solid Tumors (Any Localization)
Name | Location |
|---|
